New Trial: CBT After Esketamine Lowers Relapse Risk

What the CBT-ENDURE Trial Found

A major new randomized trial published in The Journal of Clinical Psychiatry in May 2026 offers some of the clearest evidence yet that ketamine-based treatment works best as part of a broader therapeutic plan — not as a standalone solution.

The CBT-ENDURE randomized trial enrolled patients with major depressive disorder (MDD) and active suicidal ideation who were receiving esketamine — the nasal-spray formulation of ketamine marketed as Spravato. Researchers split participants into two groups: one received esketamine alone, the other received esketamine paired with a structured 16-week course of cognitive behavioral therapy (CBT). The outcome was unambiguous. The combination group showed significantly greater reductions in both suicidal ideation and overall depression severity compared to those receiving esketamine without accompanying psychotherapy.

Ketamine-based treatments — including both esketamine and the racemic ketamine used widely in telehealth infusion and oral lozenge protocols — have long been recognized for their rapid onset. Where traditional antidepressants can take weeks to produce measurable change, ketamine often delivers relief within hours or days. The persistent clinical question has been durability: how long does that relief last, and what can extend it? CBT-ENDURE is one of the most rigorous answers to date.

Why This Research Matters for Online Ketamine Patients

For anyone exploring ketamine treatment through a telehealth provider, this trial sends a clear signal: the medication is a powerful starting point, but it produces the best long-term outcomes when paired with structured psychological support.

This finding reinforces what more careful online ketamine clinics have been building into their protocols for years. Reputable providers increasingly require or strongly encourage patients to engage in psychotherapy — whether CBT, integration therapy, or another evidence-based modality — alongside their ketamine regimen. The CBT-ENDURE trial now backs that clinical recommendation with hard randomized trial data.

For patients with major depression and suicidal ideation specifically, the implications are significant. These are the patients for whom treatment-resistant depression carries the greatest risk, and for whom the rapid anti-suicidal effects of ketamine are most clinically urgent. The fact that adding structured CBT produced meaningfully better outcomes on both depression severity scores and suicidal ideation measures means the combination protocol should be a standard expectation — not an optional add-on that only the most thorough providers offer.

What This Means for Telehealth Ketamine Access

Telehealth ketamine providers operate in a space where care quality varies considerably. Some platforms offer minimal follow-up — a prescription and little else. Others build in psychiatric check-ins, therapist coordination, and integration support. The CBT-ENDURE data makes it easier to distinguish between these tiers, and gives patients a concrete question to ask when evaluating providers: What psychological support do you offer or coordinate alongside treatment?

This research also speaks to the ongoing policy conversation around telehealth ketamine oversight. As state medical boards and federal agencies continue scrutinizing online prescribing practices, evidence that outcomes improve significantly when ketamine is paired with structured therapy could influence minimum-care standards for providers. Clinics that have already built CBT referral networks or integration sessions into their model are positioned ahead of where regulation may eventually land.

For patients in states with limited in-person psychiatric resources, the telehealth model remains the most accessible route to both ketamine and therapy — two treatments that, according to this trial, are most effective together. Choosing a provider that facilitates or coordinates both is now an evidence-backed priority, not just a preference.

Practical Questions to Ask Your Provider

The CBT-ENDURE results translate directly into a checklist for patients evaluating online ketamine options:

• Does intake screening ask about your therapy history? A thorough safety assessment should evaluate psychological support structure, not just medical history.
• Does the clinic offer integration sessions or therapist referrals? Integration therapy — structured reflection after ketamine treatment — mirrors the CBT component studied in this trial and is increasingly offered through telehealth platforms.
• Is there a sustained follow-up plan? The 16-week CBT protocol in CBT-ENDURE wasn't a one-time session. Reputable providers build ongoing check-ins and monitoring into their treatment timelines, especially for high-risk patients.
• Are there escalation protocols for active suicidal ideation? Online providers treating this population should have clear crisis pathways and coordination with emergency care built into their model.
• Does the provider communicate with your existing mental health team? The most effective ketamine care is integrated care — your ketamine provider and your therapist or psychiatrist should not be operating in silos.

One practical note on cost: adding CBT to a ketamine protocol does mean additional out-of-pocket expense, particularly if therapy sessions aren't covered by your insurance plan. However, the durability benefit — fewer relapses, longer periods of remission — may reduce the frequency of costly repeat ketamine courses over time. Ask prospective providers whether they have referral relationships with behavioral health therapists and whether their intake coordinators can help you understand your coverage options before committing to a treatment plan.